Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands the universe of inhalable drug therapies.
iSPERSE™ is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs.
iSPERSE™ can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids via the respiratory system for the treatment of both respiratory and non-respiratory diseases.
Can be used with a broad range of drugs, small molecule to biologic
Can deliver large doses into lungs (tens of milligrams) with high lung delivery efficiency
Can be used with almost any device (ie, metered-dose, reservoir, or blister-based inhalers)
Avoids first-pass effect and systemic side-effects, with improved PK profile compared to oral delivery
Requires low inspiratory flow for penetration deep into lung, based on high dispersibility
Broad IP portfolio into 2030s
PULMATRiX is currently
studying the potential for iSPERSE™
to improve the lives of patients living with:
AK Curran and DL Hava. 2021. Allergic diseases caused by Aspergillus
species in patients with cystic fibrosis. Antibiotics 10: 357.
DL Hava, L Tan, P Johnson, AK Curran, J Perry, S Kramer, K Kane,
P Bedwell, G Layton, C Swann, D Henderson, N Khan, L Connor,
L McKenzie, D Singh, and J Roach. 2020. A phase 1/1b study of
PUR1900, an inhaled formulation of itraconazole, in healthy
volunteers and asthmatics to study safety, tolerability and
pharmacokinetics. British Journal of Clinical Pharmacology 86: 723–733.
D Edwards, A Hickey, R Batycky, L Griel, M Lipp, W Dehaan, R Clarke,
DL Hava, J Perry, B Laurenzi, AK Curran, BJ Beddingfield,
C Roy, T Devlin, and R Langer. 2020. A new natural defense
against airborne pathogens. QRB Discovery: 1–28.
J Perry, B Trautman, J Takher‐Smith, S Kramer, K Kane, M Silverman,
L Tan, S Haughie, W Richter, V Kirkov, S Arsova, J Ward, and
DL Hava. 2019. Particle size and gastrointestinal absorption
influence tiotropium pharmacokinetics: a pilot bioequivalence
study of PUR0200 and Spiriva HandiHaler. British Journal of
Clinical Pharmacology 85: 580–589.
PW Andreotta, S Arold, J Kenyon, D Spicer, P Woodman, E Berry,
T Brogan, S Kong, P Okerholm, V Russell, RW Clarke, and DL Hava.
2018. Inhaled calcium salts inhibit tobacco smoke-induced
inflammation by modulating expression of chemokines and cytokines.
Pulm Pharmacol Ther 53: 86–99.
D Singh, A Ravi, K Kane, T Schmalbach, and DL Hava. 2018.
The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a
novel tiotropium formulation, in chronic obstructive pulmonary disease.
British Journal of Clinical Pharmacology 84: 2097–2105.
KA Provost, M Smith, SP Arold, DL Hava, and S Sethi. 2015. Calcium restores the macrophage response to nontypeable haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 52: 728–737.
O Holz, H Biller, M Mueller, K Kane, M Rosano, J Hanrahan, DL Hava, and JM Hohlfeld. 2015. Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial. BMC Pharmacology and Toxicology 16.
As we advance our mission to develop and commercialize novel and transformational medicines, we regularly share the progress of our research.
To learn more about our science and research findings, download these PDFs: